Stockreport

Aura Bio gains after mid-stage data for lead asset in ocular cancer [Seeking Alpha]

Aura Biosciences, Inc.  (AURA) 
PDF control rate in a Phase 2 trial for patients with early-stage choroidal melanoma, a type of ocular cancer. The 22-patient open-label study also indicated that 90% of 1 [Read more]